Emmessar Biotech & Nutrition Ltd
- Market cap
- ₹ 11 Cr.
- P/E
- 29.1x
- P/B
- 1.37x
- 52-week range
- 18.42 – 33.38
- ROE
- 6%
- ROCE
- 7.3%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Chemicals & Petrochemicals
- Industry
- Commodity Chemicals
- Listed on
- BSE
About
Emmessar Biotech and Nutrition Limited is an India-based global healthcare company that manufactures and markets healthcare and nutritional products. The Company operates through two segments: Healthcare and Rent on leasehold land. The Company's product portfolio includes dermatology, muscular pains and functions, osteoporosis, general health, anti-ageing, cosmetics, and all types of burns including radiation. Dermatology category includes products for obstinate skin problems. Muscular Pains & Functions category includes solutions for muscle problems. Osteoporosis category includes solutions to bone problems. General Health category includes treatments for various chronic physical ailments. Anti-Ageing category includes products designed to combat the signs of aging. Cosmetics category includes cosmetic products for various skin types. All types of burns, including the radiation category, include treatments for all types of burns, including those caused by radiation.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Commodity Chemicals: 75 companies →Emmessar Biotech & Nutrition Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)29.1 against a typical 22.7: pricier than most peers (1st = cheapest).42nd of 72
- Sales growth−33.3% against a typical +12.7% from a year earlier.58th of 65
- Profit growth−23.5% against a typical +13.6% from a year earlier.34th of 49
- Share price, 3 months−9.1% against a typical −2.2%.43rd of 65
- Size₹ 10.5 Cr. market value against a typical ₹ 131.2 Cr. (1st = largest).62nd of 69
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| OPM % | −275% | −63.6% | −487.5% | −350% | −23.5% | −280% | −330% | −300% | −411.1% | −377.8% | −411.1% | −583.3% |
| Other Income | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax % | 31% | 56.7% | −285.7% | 43.8% | 31.7% | 84.6% | 126.9% | 25% | 21.4% | 8.3% | 57.1% | 17.7% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 |
| EPS in Rs | 0.4 | 0.26 | 0.54 | 0.18 | 0.56 | 0.04 | −0.14 | 0.34 | 0.22 | 0.24 | 0.06 | 0.26 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −15%
- 5 Years
- −44%
- 3 Years
- −29%
- TTM
- −48%
- 10 Years
- 14%
- 5 Years
- −21%
- 3 Years
- −4%
- TTM
- −3%
- 10 Years
- 2%
- 5 Years
- −7%
- 3 Years
- 2%
- TTM
- —
- 10 Years
- 15%
- 5 Years
- 7%
- 3 Years
- 7%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Emmessar Biotech & Nutrition Ltd | ₹ 22.99 | ₹ 11 Cr. | 29.1x | 1.4x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,748.00 | ₹ 4,19,394 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Srinivasa Raghavan M Ayyangar
- Executive Chairman of the Board, Managing Director
- Jeyavel Balaiah Nadar
- Chief Financial Officer, Whole Time Director
- Priyanka Omprakash Sharma
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.